Myostatin Inhibitor Research Guide

Full name: Myostatin Inhibitor Peptides (Anti-GDF-8)

Synthetic peptides blocking myostatin signaling, the primary negative regulator of muscle mass. Multiple approaches including propeptide mimics and receptor-blocking peptides.

How Myostatin Inhibitor Works

Propeptide mimics bind mature myostatin; peptide aptamers block ActRIIB; small antagonists compete for receptor. All prevent myostatin-mediated suppression of muscle growth.

Dosing Protocol

• Typical dose: 50-500 mcg
• Frequency: 3-7x per week
• Duration: 4-12 weeks
• Route: Subcutaneous

Reported Benefits

• Muscle growth promotion
• Strength increase
• Myostatin blockade
• Muscle wasting treatment potential
• Metabolic improvement

Potential Side Effects

• Limited safety data
• Tendon stress potential
• Cardiac hypertrophy risk (theoretical)

Research Citations

1. Myostatin propeptide peptides as growth enhancers (2022) - Increased hindlimb muscle mass by 25% with improved grip strength and endurance.
2. Clinical landscape of myostatin inhibition (2023) - Anti-myostatin approaches show 3-5% lean mass gains; combination with exercise adds 8% benefit.

Related Muscle Growth Compounds

• Follistatin 344 - Full Profile
• ACE-031 - Full Profile
• IGF-1 LR3 - Full Profile
• MGF (Mechano Growth Factor) - Full Profile
• LGD-4033 - Full Profile
• YK-11 - Full Profile

View full Myostatin Inhibitor profile with 3D molecule viewer →